Imaxio Signs Licence Agreement to Develop Veterinary Vaccines
FRANCE - Imaxio, a biopharmaceutical company specialized in vaccines and genomics, announced that it has signed a license option agreement with a major animal health laboratory, a top ten company globally in its sector. The aim of the agreement is to develop a number of veterinary vaccines using Imaxio's immuno-enhancing IMX313 technology.